Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Not applicable Interventional

A Trial to Reduce Readmissions Using Motivational Interviewing and Interactive Voice Response

NCT01855022
View directory record Official record
Conditions
Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
MI + IVR
Behavioral
Lead sponsor
Asante Health System
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Grants Pass, Oregon • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829
View directory record Official record
Conditions
COPD
Interventions
Placebo, SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg, SUN-101 50 mcg, Aclidinium
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 16, 2026, 3:53 PM EDT
Withdrawn No phase listed Observational

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

NCT01809730
View directory record Official record
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 16, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA

NCT05254431
View directory record Official record
Conditions
COPD, OSA
Interventions
Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease

NCT00034112
View directory record Official record
Conditions
Emphysema
Interventions
osteopathic manipulative treatment
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 16, 2026, 3:53 PM EDT
Active, not recruiting Not applicable Interventional

Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD

NCT05718102
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Population-health management
Other
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Minneapolis, Minnesota • Portland, Oregon • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Completed No phase listed Observational

Replication of the INSPIRE Trial in Healthcare Claims Data

NCT05179512
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Tiotropium, salmeterol-fluticasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
98,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 16, 2026, 3:53 PM EDT
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Not applicable Interventional

The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations

NCT01582958
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Osteopathic Manipulative Treatment (OMT), sham omt
Procedure · Other
Lead sponsor
Michigan State University
Other
Eligibility
49 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

NCT00062582
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
32
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in California, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease

NCT01448850
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MEDI8968 600 mg IV, 300 mg SC, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
45 Years to 75 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Peoria, Arizona • Clearwater, Florida • Duluth, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Effect of Ventilation-Feedback Training on Exercise Performance in COPD

NCT00037973
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ventilation feedback, exercise
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 16, 2026, 3:53 PM EDT
Completed No phase listed Observational

Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients

NCT05518981
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Respiratory Remote Patient Monitor (Spire Health Tag)
Device
Lead sponsor
Spire, Inc.
Industry
Eligibility
Not listed
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population

NCT01619098
View directory record Official record
Conditions
Hospital Readmission, Post-discharge Care Transitions, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Patient Navigator, Usual care
Other
Lead sponsor
Alison Galbraith
Other
Eligibility
18 Years and older
Enrollment
1,510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cambridge, Massachusetts • Everett, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 16, 2026, 3:53 PM EDT
Recruiting Phase 3 Interventional

Trial to Determine Effective Aspirin Dose in COPD

NCT05265299
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Aspirin 81mg, Aspirin 162 mg, Aspirin 325mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT05573464
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Newport Beach, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Internet-based Cognitive-behavioral Treatment for Insomnia in COPD Patients Undergoing Pulmonary Rehabilitation

NCT04700098
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Insomnia
Interventions
Internet-based behavioral treatment for insomnia, Online insomnia patient education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Active, not recruiting Not applicable Interventional

Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke

NCT07118189
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
N95 masks and indoor air cleaner
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Enhancement of Corticosteroid Efficacy in COPD

NCT02340520
View directory record Official record
Conditions
COPD
Interventions
Theophylline, Roflumilast
Drug
Lead sponsor
UConn Health
Other
Eligibility
45 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 16, 2026, 3:53 PM EDT
Terminated No phase listed Observational

Clinical Feasibility of a Non-invasive Wearable Acoustic Device for Measuring Air Trapping in COPD

NCT04450368
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Sylvee
Device
Lead sponsor
Respira Labs, Inc
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

PATient Navigator to rEduce Readmissions

NCT02114515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction, Pneumonia
Interventions
Hospital usual care, Navigator intervention, Peer-led telephone support line
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 16, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema

NCT04801108
View directory record Official record
Conditions
Emphysema or COPD
Interventions
Robotic or VATS lobar fissure completion, Endobronchial valves placement
Procedure · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 3:53 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

NCT01043601
View directory record Official record
Conditions
COPD
Interventions
Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 16, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 16, 2026, 3:53 PM EDT